[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiation-induced-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiation-induced-disorder":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100414454","functional-lung-avoidance-spect-guided-radiation-therapy-of-lung-cancer-100414454",false,"NCT04676828","Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer","Functional Lung Avoidance SPECT-guided (ASPECT) Radiation Therapy for Lung Cancer Patients: Phase II Randomised Clinical Trial","ASPECT","Inclusion Criteria:\n\n* histologically verified lung cancer (small-cell and non-small cell lung cancer)\n* referred for radiotherapy with curative intent\n* radiation dose of 60-66 Gy given in 2-Gy fractions, other dose levels and fractionation schedules accepted, as per site standard\n* concurrent chemotherapy is accepted\n* patients with oligometastatic disease are allowed, where metastasis have been ablated with surgery or radiotherapy\n* receiving (chemo)-radiotherapy to the thoracic disease with curative intent\n* adults over 18, that have given oral and written informed consent before patient registration.\n\nExclusion Criteria:\n\n* concurrent immunotherapy\n* previous radiotherapy to the thorax\n* other uncontrolled malignancies; any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol","ALL","18 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"NA","Study aims to determine if functional lung avoidance based on perfusion single photon emission (SPECT)\u002FCT scan, improves toxicity outcomes for patients with advanced lung cancer undergoing chemo-radiotherapy. Functional avoidance implies a dose plan that takes functional distribution in the lung into account, and avoids highly functional lung volumes sparing them from radiation.",[27,28,29,30,31],"Lung Cancer","Radiation-Induced Disorder","Radiation Pneumonitis","Pulmonary Disease","Lung Function Decreased",[33,34,35],"radiation-induced lung toxicity","functional avoidance methodology","radiation therapy of lung cancer","RECRUITING","2026-02-22",{"date":39,"type":40},"2026-02-24","ACTUAL",{"date":42,"type":40},"2021-12-01",{"date":44,"type":21},"2028-12-01",{"name":46,"class":47},"University of Aarhus","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100578807","gene-and-molecular-pathways-of-ozone-treatment-response-in-gynecological-tumor-patients-with-chronic-pelvic-pain-secondary-to-cancer-treatment-100578807","NCT06816095","Gene and Molecular Pathways of Ozone Treatment Response in Gynecological Tumor Patients With Chronic Pelvic Pain Secondary to Cancer Treatment","Gene and Molecular Pathway Characterization of the Response to Ozone Treatment in Gynecological Tumor Patients With Chronic Pelvic Pain Secondary to Radio-chemotherapy","OzoGynEpigen","Inclusion Criteria:\n\n* Adult women (\\>=18 years old) with gynecological tumors treated with radiotherapy-chemotherapy.\n* Cancer disease is stable or in remission.\n* Life expectancy \\> = 6 months.\n* Patients included in the group of patients with pelvic pain must have a clinical, radiological, endoscopic, or histopathological diagnosis that their pain is not secondary to the oncological process.\n* Patients included in the group of patients with pelvic pain must have pain for \\>= 3 months duration, with an intensity \\>= 3 on the Visual Analog Scale (VAS), or classified as toxicity \\>= Grade-2 of the CTCAE v.5.0 of the National Cancer Institute of the USA.\n* Signed and dated informed consent specific to this study.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old.\n* Severe psychiatric disorders.\n* Inability to complete the quality of life questionnaires.\n* Active neoplasia requiring recent initiation (\\\u003C 3 months) of systemic or local treatment.\n* Life expectancy (for any reason) \\\u003C 6 months.\n* Failure to meet all inclusion criteria","FEMALE",{"count":58,"type":21},40,"OBSERVATIONAL","Gynecological cancers, including those affecting the ovaries, uterus, and cervix, represent a significant health burden for women. While survival rates have improved, many women experience chronic pelvic pain secondary to cancer treatment, especially radiotherapy and chemotherapy. This treatment-induced pelvic pain can be of difficult management and significantly affects patients' quality of life.\n\nIn our experience, ozone therapy has emerged as a promising complementary treatment for pain relief in patients with chronic diseases, including side effects of cancer treatment. However, the genetic and epigenetic mechanisms influencing its effectiveness have not yet been thoroughly studied.\n\nThe aim of this prospective study is to analyze how ozone therapy modulates the expression of certain genes and its impact on epigenetic clocks, which could help predict pain response.",[62,28,63,64,65],"Chronic Pelvic Pain Syndrome (CPPS)","Radiotherapy Side Effects","Side Effect of Chemotherapy","Gynecological Cancers",[28,63,67,62,65,68,69,70,71,72,73,74],"Cancer survivors","gene expression","epigenetic clocks","side effects of cancer treatment","Toxicity of chemotherapy","Ozone therapy","Quality of Life","oxidative stress","2025-02-10",{"date":77,"type":40},"2025-02-12",{"date":75,"type":40},{"date":80,"type":21},"2027-08-14",{"name":82,"class":47},"Bernardino Clavo, MD, PhD",1]